The Memory of the Heart and the Storm of Pregnancy: Biochemical and Clinical Frontiers of Secondary Prophylaxis in Rheumatic Heart Disease

Key Takeaways

The cellular memory of a streptococcal infection presumed to be left in the past can transform into a dormant storm within the heart valves under the physiological and hemodynamic burden imposed by pregnancy. In a pregnant patient diagnosed with Rheumatic Heart Disease, initiating secondary prophylaxis is not a matter of clinical preference, but an absolute obligation to safeguard both fetal and maternal lives. Chronological age thresholds alone are insufficient when determining the duration of prophylaxis; rather, the elapsed time since the most recent rheumatic attack serves as the primary decisive parameter. Accordingly, a documented history of infection at age 31 extends the necessity of prophylaxis continuously until at least age 41 or 42. Given that a vast majority of reported penicillin allergy histories do not represent true IgE-mediated Type 1 hypersensitivity reactions, initial protection initiated with safe oral macrolides during pregnancy should be transitioned to the gold-standard Benzathine Penicillin G regimen following immunological confirmatory testing. Owing to the limited availability of oral erythromycin formulations in clinical practice in Türkiye, Azithromycin stands out as the most rational primary oral alternative during pregnancy. Nevertheless, if erythromycin is to be utilized according to global literature, the Estolate form—which induces cholestatic liver injury in the maternal liver due to its 2′-position propionyl ester linkage—must be strictly avoided, favoring Ethylsuccinate or Base formulations. Conversely, Sulfadiazine is strictly contraindicated during the third trimester as it competitively disrupts fetal albumin-bilirubin binding, carrying a severe risk of precipitating neonatal Kernicterus. Finally, while routine infective endocarditis prophylaxis is not indicated during vaginal delivery in isolated native valve involvement, maintaining secondary prophylaxis to prevent rheumatic fever recurrences with meticulous consistency throughout pregnancy, labor, and the puerperium represents the cornerstone of perinatological success.

Historical and Philosophical Perspective: Immunological Memory Beyond Time

One of the deepest tragedies in medical history is the phenomenon of molecular mimicry, wherein the structural echoes of a microorganism continue to resound within host tissue decades after the pathogen has been completely eradicated. Acute Rheumatic Fever (ARF), famously described by 19th-century clinicians as a disease that “licks the joints but bites the heart,” represents the most stark illustration of the immune system becoming alienated from its own native tissue. Epitope homology between the M protein embedded in the cell wall of Streptococcus pyogenes and structural proteins of the human cardiac valve—such as myosin, tropomyosin, and vimentin—demonstrates how immunological memory can mutate into a destructive weapon. Even after the bacteria are cleared, CD4+ T lymphocytes and antibody-secreting plasma cells imprint themselves upon the endocardial matrix. This imprinting leaves silent yet indelible scars (rheumatic scar) across the valvular leaflets.

Within the life cycle of a woman, pregnancy represents an extraordinary phase wherein physiological reserves and adaptive capacities are tested to their utmost limits. Pregnancy is not merely a biological process, but a delicate philosophical symphony balancing maternal immune tolerance against hemodynamic expansion. However, for a heart bearing the imprinted scars of prior rheumatic carditis, pregnancy can reignite a dormant fire. As cardiac output and circulating blood volume surge by up to 50%, even a millimetric valvular deformity can exhaust maternal cardiovascular reserve. Secondary prophylaxis serves precisely at this juncture as a rational, protective shield wielded by the physician against the destructive momentum of cellular memory.

Clinical Case Presentation and Hemodynamic Risk Assessment

Our outpatient evaluation centers on a 32-year-old female patient at 24 weeks of gestation (6th month of pregnancy). Transthoracic echocardiographic (TTE) examination revealed a mildly deformed aortic valve with structural changes; color Doppler analysis demonstrated Grade 1 (mild) aortic regurgitation and Grade 1 (mild) mitral regurgitation. Detailed history taking established a background of recurrent upper respiratory tract infections during childhood, with the most recent documented Group A Beta-Hemolytic Streptococcal (GAS) pharyngitis occurring just one year prior, at age 31. The patient remains actively employed in a crowded work environment characterized by high human circulation. Upon inquiring into her medical background, an alleged “penicillin allergy” reported by her mother during childhood was noted.

International cardiology and infectious disease consensus guidelines (AHA, ESC, WHO) classify mild valvular regurgitation combined with distinct structural deformities as chronic sequelae of prior rheumatic carditis (residual Rheumatic Heart Disease – RHD). The patient’s continued occupation in an enclosed, populous workplace exponentially increases her exposure frequency to virulent community strains of Streptococcus pyogenes, rendering the risk of re-infection a continuous threat.

The transition into the second and third trimesters introduces profound maternal physiological alterations that push the cardiac workload in this patient toward a critical threshold. From mid-gestation onward, cardiac output and stroke volume rise by 30% to 50%, accompanied by an increase in resting heart rate of 10 to 20 beats per minute. In a patient with baseline Grade 1 aortic and mitral regurgitation, a single episode of streptococcal pharyngitis under these conditions of physiological hypervolemia and elevated output will reactivate both humoral and cell-mediated immunity. A recurrence of Acute Rheumatic Fever can rapidly destabilize mild regurgitative leisons into severe valvular dysfunction, acute left ventricular decompensation, pulmonary venous congestion, and catastrophic perinatological complications threatening both maternal and fetal lives. Evaluating these anatomical, environmental, and pregnancy-specific risk factors in unison makes the immediate initiation of secondary antibiotic prophylaxis an unyielding clinical imperative.

Precise Calculations: Determining Prophylaxis Duration and Age Thresholds

The maintenance duration of secondary ARF prophylaxis is categorized based on the number of previous rheumatic attacks, the historical presence of carditis, the severity of persistent valvular damage (residual RHD), the time elapsed since the last attack, and individual exposure risks. According to standard consensus criteria established by the American Heart Association (AHA) and World Health Organization (WHO), individuals who have experienced rheumatic carditis with persistent valvular disease must continue prophylaxis for at least 10 years following the last documented streptococcal episode or until age 40, whichever duration is longer.

A rigorous analysis of our index patient’s chronological parameters reveals that she is currently 32 years old and experienced her last streptococcal infection at age 31. Applying the guideline rule of “at least 10 years post-last attack” projects the required protection timeline to age 41. Because this timeframe exceeds the alternative threshold of age 40, the longer period must govern clinical management, dictating continuous secondary prophylaxis until at least age 41–42 (10 uninterrupted years from the last episode). Given her sustained exposure in a crowded work setting and dual-valve residual involvement (aortic and mitral), the echocardiographic progression of her valvular deformities and environmental risks should be formally reassessed at age 41–42 to determine whether lifelong prophylaxis is warranted.

Deconstructing the Penicillin Allergy Myth: An Immunological Filter

The history of penicillin allergy reported by the patient’s mother represents a clinical bottleneck in selecting the appropriate prophylactic agent. However, extensive epidemiological data and allergy-immunology literature demonstrate that over 90% of self-reported or family-reported penicillin allergies do not constitute true IgE-mediated Type 1 (anaphylactic) hypersensitivity reactions. This prevalent misconception typically stems from childhood viral exanthems, gastrointestinal intolerance, or non-specific adverse drug events misattributed to penicillin.

Antibacterial Management & Safety Profile Matrix

Antibacterial Regimen	Dose and Route	Frequency	Safety Level in Pregnancy	Clinical Features and Contraindications
Benzathine Penicillin G (BPG)	1,200,000 Units Deep IM	Every 3–4 weeks	Safe (First-line if non-allergic)	Fully safe in pregnancy. Offers the highest adherence and efficacy in preventing recurrences.
Azithromycin	250 mg Oral	Once daily	Safe / First Choice in Türkiye	Primary option in Türkiye due to oral erythromycin shortage. Single daily dose enhances compliance.
Erythromycin Ethylsuccinate / Base	250 mg Oral	Twice daily	Conditionally Safe (Global Standard)	Global standard alternative. Estolate form is strictly contraindicated in pregnancy.
Sulfadiazine	1.0 g Oral	Once daily	Strictly Contraindicated in 3rd Trimester	Alternative if penicillin and macrolides are not tolerated. Carries Kernikterus risk in late pregnancy.

Intramuscular Benzathine Penicillin G (BPG) provides superior protection compared to oral alternatives in preventing streptococcal pharyngitis and ARF recurrences while completely eliminating failures related to patient non-compliance. The incidence of anaphylaxis with long-term BPG administration remains exceptionally low (~0.2%), rendering its clinical benefit far superior to its risks.

The rational protocol to pursue involves referring the patient during pregnancy or immediately postpartum to an Allergy and Immunology specialist for formal penicillin skin testing (skin prick and intradermal testing). If IgE-mediated hypersensitivity is ruled out, the patient should be transitioned without delay to deep intramuscular BPG injections every 3 to 4 weeks. However, pending formal allergic verification, the patient must be managed under the assumption of penicillin allergy, and secondary prophylaxis must be initiated immediately using a pregnancy-compatible oral macrolide regimen.

Pharmacotherapeutic Minefield: Biochemistry and Molecular Analysis

Pharmacological agents selected for secondary prophylaxis in a pregnant patient with suspected penicillin allergy must be evaluated meticulously regarding maternal-fetal safety profiles and bacteriostatic potency against Streptococcus pyogenes.

Owing to the restricted availability of oral erythromycin formulations in clinical practice in Türkiye, oral Azithromycin (250 mg/day) serves as the primary and most practical oral macrolide choice. Azithromycin boasts an excellent safety profile during pregnancy (FDA Category B), a prolonged tissue half-life, and a convenient once-daily dosing regimen that optimizes patient compliance.

Nevertheless, molecular nuances regarding erythromycin usage detailed in global pharmacotherapy literature and international guidelines remain critically important:

The Erythromycin Estolate formulation induces significant elevations in serum transaminases (SGOT/ALT) and gamma-glutamyl transferase, intrahepatic cholestasis, and clinical jaundice in pregnant women. Clinical studies indicate that over 9% of pregnant patients receiving the estolate salt develop subclinical or overt hepatotoxicity. Structural biochemical analyses confirm that the 2′-position propionyl ester linkage of the molecule is responsible for this hepatic injury, an adverse effect absent in other salt forms. Therefore, if erythromycin is ever prescribed to a pregnant patient, the Estolate form must be strictly avoided, selecting exclusively Ethylsuccinate or Base formulations. Across all macrolide therapies, a 3% to 30% baseline rate of macrolide resistance among local GAS isolates must be factored into clinical risk assessments.

Sulfadiazine represents another effective agent widely utilized for secondary ARF prophylaxis in non-pregnant populations. However, sulfonamides readily cross the placental barrier into the fetal circulation, where they competitively displace bilirubin from its binding sites on fetal albumin. Administering sulfadiazine during late pregnancy or the third trimester dangerously elevates unconjugated serum bilirubin levels in the fetus, leading to severe neonatal hyperbilirubinemia and Kernikterus (bilirubin encephalopathy). As our patient is entering her late second trimester, sulfadiazine is strictly contraindicated throughout the remainder of her pregnancy.

Perinatological and Cardiological Symphony: The “Pregnancy Heart Team”

Managing a pregnant patient with Rheumatic Heart Disease transcends the domain of a single specialty. In alignment with the European Society of Cardiology (ESC) Guidelines for the Management of Cardiovascular Diseases during Pregnancy, such cases must be co-managed by a dedicated “Pregnancy Heart Team” comprising specialists in Cardiology, Maternal-Fetal Medicine (Perinatology), and Infectious Diseases.

As maternal blood volume expansion peaks around 24 to 28 weeks of gestation, the concomitant rise in stroke volume can accentuate the hemodynamic impact of mild aortic and mitral regurgitation. To distinguish physiological pregnancy symptoms from cardiac decompensation, serial echocardiographic evaluations should monitor valvular regurgitation severity, left ventricular end-diastolic dimensions, and estimated pulmonary artery pressures. Furthermore, hypertensive disorders such as preeclampsia increase left ventricular afterload, exacerbating regurgitant fractions; thus, strict blood pressure control is paramount.

A clear clinical distinction must be drawn between Secondary ARF Prophylaxis and Infective Endocarditis (IE) Prophylaxis. According to current AHA and ESC guidelines, routine antibiotic endocarditis prophylaxis is not recommended for uncomplicated spontaneous vaginal or cesarean delivery in patients with isolated native valve disease (e.g., mild rheumatic aortic/mitral regurgitation) in the absence of a prosthetic valve or prior endocarditis history. In contrast, secondary ARF prophylaxis aimed at preventing recurrent streptococcal infections must continue without interruption throughout pregnancy, labor, and the postpartum period. Vaginal delivery remains the preferred mode of labor for cardiovascular stability, reserving cesarean section strictly for obstetric indications or acute cardiac breakdown.

Molecular Footnotes and Rigorous Evidence

Molecular mimicry between the M protein of Streptococcus pyogenes and human cardiac tissues is driven by the infiltration and accumulation of CD4+ T cells within the subendocardium and valvular chordae. Volume overload during pregnancy raises left ventricular end-diastolic pressure (LVEDP), thereby escalating mechanical shear stress across the valvular leaflets. This mechanical insult can reactivate inflammatory cytokine cascades (TNF-alpha, IL-6) within subclinical rheumatic lesions. Penicillin hypersensitivity reflects a Type 1 IgE-mediated response directed against penicilloyl major determinants and minor determinant mixtures (MDM). In the macrolide class, Erythromycin Estolate induces cholestatic hepatotoxicity due to its 2′-propional ester moiety acting as a direct biliary toxin combined with a hypersensitivity reaction; conversely, Azithromycin’s 15-membered azalide ring structure completely lacks this cholestatic toxicity profile. Sulfonamides in the Sulfadiazine regimen bind with high affinity to Site II on serum albumin, displacing unconjugated bilirubin; free lipophilic bilirubin readily crosses the immature fetal blood-brain barrier, depositing within the basal ganglia and causing irreversible neuronal injury (Kernikterus).

“Medicine is a timeless art of wisdom that fuses the unyielding data of science with the fragile beauty of the human spirit.” — The Vault

References

1. WHO guideline on the prevention and diagnosis of rheumatic fever and rheumatic heart disease. https://iris.who.int/server/api/core/bitstreams/fbd835e1-b9b7-414a-b6aa-9c279472bbdf/content
2. Gerber MA, et al. Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: Circulation. 2009. DOI: 10.1161/CIRCULATIONAHA.109.191959
3. Clinical Guidance for Acute Rheumatic Fever. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/acute-rheumatic-fever.html
4. Ralph AP, et al. Therapeutics for rheumatic fever and rheumatic heart disease. Aust Prescr. 2022. DOI: 10.18773/austprescr.2022.034
5. Sanyahumbi A, et al. Penicillin Reactions in Patients With Severe Rheumatic Heart Disease: A Presidential Advisory From the American Heart Association. J Am Heart Assoc. 2022. DOI: 10.1161/JAHA.121.024517
6. McCormack WM, et al. Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob Agents Chemother. 1977. DOI: 10.1128/AAC.12.5.630
7. Rheumatic heart disease and pregnancy.

8. Safety of macrolide antibiotics in pregnancy: a review of the epidemiological evidence. https://www.gov.uk/government/publications/public-assessment-report-safety-of-macrolide-antibiotics-in-pregnancy-a-review-of-the-epidemiological-evidence/safety-of-macrolide-antibiotics-in-pregnancy-a-review-of-the-epidemiological-evidence
9. De Backer J, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025. DOI: 10.1093/eurheartj/ehaf193

 

Share this article

LinkedIn X Facebook WhatsApp Copy Link